16 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 10 Phase 2, 8 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Active not recruiting 1, Terminated 1 |
| Phase 1 | 8 | Completed 7, Terminated 1 |
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
Follow Medicago: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine CoVLP formulation - COVID-19 | Phase 3 | Withdrawn | Medicago | 2021-11-22 | 2023-06-02 | |
| Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19） MT-2766 High dose (3.75 µg), Placebo, MT-2766 Low dose - SARS-CoV-2 Infection | Phase 1 / Phase 2 | Terminated | Medicago | 128 | 2021-10-02 | 2023-11-07 |
| Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults Intramuscular injection, Intramuscular vaccine - SARS-CoV-2 Infection | Phase 2 / Phase 3 | Active not recruiting | Medicago | 30918 | 2020-11-19 | 2022-04-06 |
| Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older Instramuscular vaccine - Influenza | Phase 1 / Phase 2 | Completed | Medicago | 209 | 2020-11-02 | 2023-07-21 |
| Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. Intramuscular Vaccine - SARS-CoV 2 | Phase 1 | Completed | Medicago | 180 | 2020-07-10 | 2022-04-06 |
| Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine - Virus Diseases, RNA Virus Infections | Phase 3 | Completed | Medicago | 12794 | 2018-09-18 | 2023-06-23 |
| Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Quadrivalent VLP Influenza Vaccine - Virus Diseases, RNA Virus Infections | Phase 3 | Completed | Medicago | 1202 | 2017-09-29 | 2023-08-04 |
| Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults Quadrivalent VLP Vaccine, Placebo - Virus Diseases, RNA Virus Infections | Phase 3 | Completed | Medicago | 10160 | 2017-08-31 | 2023-08-14 |
| Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain) - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 1001 | 2016-04-01 | 2019-10-25 |
| Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 900 | 2016-03-02 | 2020-06-11 |
| Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 300 | 2014-07-28 | 2019-11-13 |
| Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population Non-adjuvanted low dose of quadrivalent VLP vaccine, Non-adjuvanted medium dose of quadrivalent VLP vaccine, Non-adjuvanted high dose of quadrivalent VLP vaccine - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 450 | 2014-07-16 | 2019-11-01 |
| Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults. Low dose of H7 VLP vaccine + Alhydrogel, Med dose of H7 VLP vaccine + Alhydrogel, High dose of H7 VLP vaccine + Alhydrogel - Virus Diseases, RNA Virus Infections | Phase 1 | Completed | Medicago | 100 | 2013-12-01 | 2015-09-25 |
| Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine - Virus Diseases, RNA Virus Infections | Phase 1 / Phase 2 | Completed | Medicago | 120 | 2013-10-08 | 2020-06-11 |
| Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. Low dose of H5 VLP vaccine + Alhydrogel, Med dose of H5 VLP vaccine + Alhydrogel, High dose of H5 VLP vaccine + Alhydrogel - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 390 | 2013-06-01 | 2020-06-11 |
| H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R) - Influenza A Subtype H5N1 Infection | Phase 1 | Completed | Access to Advanced Health Institute (AAHI) | 105 | 2012-09-01 | 2014-02-26 |
| Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults Dose given at Day 0 - Flu | Phase 1 | Completed | Medicago | 100 | 2011-02-01 | 2013-08-16 |
| Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine 20 micrograms dose H5 VLP, 30 micrograms dose H5 VLP, 45 micrograms dose H5 VLP - Virus Diseases, RNA Virus Infections | Phase 2 | Completed | Medicago | 255 | 2010-11-01 | 2012-07-31 |
| Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults H5 VLP pandemic influenza vaccine 5 µg, H5 VLP pandemic influenza vaccine 10 µg, H5 VLP pandemic influenza vaccine 20 µg - Virus Diseases, RNA Virus Infections | Phase 1 | Completed | Medicago | 48 | 2009-09-01 | 2010-11-04 |
Influenza, Human (13) · RNA Virus Infections (12) · Respiratory Tract Diseases (12) · Respiratory Tract Infections (12) · Virus Diseases (12) · Infections (9) · Orthomyxoviridae Infections (9) · COVID-19 (3) · Respiration Disorders (1)
Aluminum Hydroxide (2) · AS03 adjuvant (1) · Influenza Vaccines (1) · Injections, Intramuscular (1) · MT-2766 vaccine (1)
Canada (13) · United States (10) · Finland (2) · Germany (2) · Thailand (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Japan (1) · Mexico (1) · Philippines (1)
Michael Libman, MD (4) · Brian Ward, MD (2) · David J Seiden, MD (2) · Deepen Patel, MD (2) · Eric Sheldon, MD (2) · Ginette Girard, MD (2) · Luis Robles, MD (2) · Marc Dionne, MD (2) · Pierre Lachance, MD (2) · Suchet R Patel, MD (2) · Trevor Wesson, MD (2) · Brandon J Essink, MD (1) · Brian J Ward, MD (1) · David Seiden, MD (1)
PMID 31166987, PMID 33065035, PMID 21203523, PMID 26987887, PMID 33581920, PMID 34007070, PMID 35507508